Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: Rho signalling pathway inhibitors - BioAxone BioSciences

Drug Profile

Research programme: Rho signalling pathway inhibitors - BioAxone BioSciences

Alternative Names: BA 1016; BA 1037; BA 1049; BA 2017; BA 285; BA-1076; BA-207; BA-215; BA-240; Rhostatin™; ROCK2 inhibitors - BioAxone BioSciences

Latest Information Update: 05 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioAxone Therapeutic
  • Developer BioAxone Biosciences; BioAxone Therapeutic
  • Class Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Neuroprotectants; Small molecules
  • Mechanism of Action Rho GTP-binding protein-inhibitors; Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cavernous-haemangioma; Spinal cord injuries; Stroke
  • No development reported Glaucoma
  • Discontinued Cancer; Cancer metastases; Cardiovascular disorders; CNS trauma; Optic nerve disorders; Retinal disorders

Most Recent Events

  • 27 Sep 2018 BioAxone BioSciences plans phase I proof of concept trial and phase II trial of BA 1049 for Spinal cord injuries
  • 08 Aug 2018 BioAxone Biosciences receives patent allowance for BA 1049 in USA
  • 10 Jul 2018 The USPTO issues a Notice of Allowance for composition of matter patent covering BA 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top